JIN Jing
Jin Jing is an associate professor at IMM, CAMS & PUMC. She got her bachelor's degree in 2005 from the Capital Medical University and received her Ph.D. from Peking Union Medical College in 2010. Since then, she has been working with the IMM, CAMS & PUMC. In 2012, she went to the University of Virginia where she did her research as a visiting scientist.
Dr. Jin's research interest is focused on the pharmacology study and innovative drug development for inflammatory diseases, including cancer and autoimmune diseases. She has participated in the preclinical study and IND of many drugs, and 2 of them were approved by CFDA in 2016. She has published more than 50 research papers, and she was the first or corresponding author of 23 of them. As the major inventor, she has filed 19 patent applications and 4 of them have been authorized. She has been awarded 6 grants.
1. Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. Bioorganic & Medicinal Chemistry. 2021 Jan 1;29:115890.
2. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Research. 2020;48(7): 3816-3831.
3. Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists. J Med Chem . 2020 Jan 9;63(1):260-282.
4. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B .2020 Feb;10(2):276-288.
5. Discovery of 4-Methylquinazoline based PI3K inhibitors for the potential treatment of idiopathic pulmonary fibrosis. J Med Chem . 2019;62(19),8873-8879.
6. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer. Cell Mol Life Sci . 2019 Apr 12; 76(17): 3433-3447.
7. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Frontiers in pharmacology . 2019 Sep 19;10:1085.
8. The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. SLAS Discovery. 2018;23(6): 545–553.
9. Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment. Biol. Pharm. Bull . 2018,;41(4):592–596.
10. CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression. Onco Targets Ther . 2018; 11: 3671–3684.
11. Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors. Bioorganic & Medicinal Chemistry. 2018:26:2186-2197.
12. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochemical Pharmacology . 2014, Jul 1; 90(1), 50-61.
13. Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design. Eur J Med Chem . 2014 Oct 6; 85:1-15.
14. RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells. Neoplasma . 2013;60(1)92-100.
15. Synthesis and antiproliferative evaluation of novel benzoimidazole contained oxazole-bridged analogs of combretastatin A-4. Eur J Med Chem . 2013 Oct; 68:222-232
16. Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton. Bioorg Med Chem . 2012; 20(9): 2992-2999.
17. Synthesis and biological evaluation of novel quinazoline-derived human Pin1 inhibitors. Bioorg Med Chem . 2011; 19(9):2797-807.
2020, the First medical science and technology innovation competition. “bronze award”, DCMST-NHC (development center for the medical science & technology ), China.
